Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px

Product › Details

eliapixant (BAY 1817080)

	Next higher product group	P2X3 antagonist
	Status	2019-07-25 development p2 existent
	Status	2022-02-04 development end–negat
	Organisation	Bayer (Group)
	Organisation 2	Evotec AG (FSE: EVT, TecDAX)
	Today	Evotec SE (FSE: EVT, MDA X/TecDAX, Nasdaq: EVO)
	Group	Evotec (Group)
	Source	Bayer AG. (2/4/22). "Press Release: Bayer Will Discontinue Phase II Development Candidate eliapixant [only for specialized press]". Berlin.

Record changed: 2023-07-10

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for respiratory drug

[1] Enterprise Therapeutics Ltd.. (1/30/24). "Press Release: Enterprise Therapeutics Closes £26 million ($33.1 million) Series B Follow-on Financing". Brighton....
[2] Evotec SE. (2/4/22). "Press Release: Bayer Discontinues Clinical Development Candidate Eliapixant (BAY1817080), Evotec Regains the Rights to All P2X3 Assets [Ad hoc release]". Hamburg....
[3] Polyphor Ltd.. (29/10/21). "Press Release: Polyphor Shareholders Approve All Resolutions for the Planned Merger with EnBiotix at the Extraordinary General Meeting". Allschwil....
[4] Kaia Health Software GmbH. (11/30/20). "Press Release: Kaia Health and Chiesi Group Announce Strategic Partnership to Commercialise Kaia COPD Pulmonary Rehabilitation App in European Markets". Munich & Parma....
[5] Evotec SE. (7/25/19). "Press Release: P2X3 Antagonist Demonstrates Efficacy against Refractory Chronic Cough in Phase II (POC)". Hamburg....
[6] Boehringer Ingelheim. (7/18/19). "Press Release: Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement with Bridge Biotherapeutics". Ingelheim & Seongnam....
[7] MaRS Innovation. (2/27/19). "Press Release: MaRS Innovation Adds to Growing Portfolio with Two New LAB150 Projects to Create Novel Therapeutics for Cystic Fibrosis and Respiratory Syncytial Virus". Toronto, ON....
[8] Enterprise Therapeutics Ltd.. (4/12/18). "Press Release: Enterprise Therapeutics Raises £29 Million ($41 Million USD) Funding". Brighton....
[9] Gimv. (3/8/17). "Press Release: Gimv Co-leads EUR 43.5 million Financing of Breath Therapeutics". Antwerp....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)